Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13,554 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancer.
Zammarrelli WA 3rd, Ma W, Espino K, Gordhandas S, Yeoshoua E, Ehmann S, Zhou Q, Iasonos A, Abu-Rustum NR, Aghajanian C, Green AK, Rubinstein MM, Makker V. Zammarrelli WA 3rd, et al. Among authors: ma w. Gynecol Oncol. 2023 Nov;178:27-35. doi: 10.1016/j.ygyno.2023.09.010. Epub 2023 Sep 23. Gynecol Oncol. 2023. PMID: 37748268 Free PMC article.
A multimodality triage algorithm to improve cytoreductive outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center team ovary initiative.
Straubhar AM, Filippova OT, Cowan RA, Lakhman Y, Sarasohn DM, Nikolovski I, Torrisi JM, Ma W, Abu-Rustum NR, Gardner GJ, Sonoda Y, Zivanovic O, Chi DS, Long Roche K. Straubhar AM, et al. Among authors: ma w. Gynecol Oncol. 2020 Sep;158(3):608-613. doi: 10.1016/j.ygyno.2020.05.041. Epub 2020 Jun 6. Gynecol Oncol. 2020. PMID: 32518012 Free PMC article.
Bevacizumab in advanced endometrial cancer.
Rubinstein MM, Dickinson S, Narayan P, Zhou Q, Iasonos A, Ma W, Lakhman Y, Makker V. Rubinstein MM, et al. Among authors: ma w. Gynecol Oncol. 2021 Jun;161(3):720-726. doi: 10.1016/j.ygyno.2021.04.016. Epub 2021 Apr 22. Gynecol Oncol. 2021. PMID: 33894982 Free PMC article.
Microsatellite Instability-High Endometrial Cancers with MLH1 Promoter Hypermethylation Have Distinct Molecular and Clinical Profiles.
Manning-Geist BL, Liu YL, Devereaux KA, Paula ADC, Zhou QC, Ma W, Selenica P, Ceyhan-Birsoy O, Moukarzel LA, Hoang T, Gordhandas S, Rubinstein MM, Friedman CF, Aghajanian C, Abu-Rustum NR, Stadler ZK, Reis-Filho JS, Iasonos A, Zamarin D, Ellenson LH, Lakhman Y, Mandelker DL, Weigelt B. Manning-Geist BL, et al. Among authors: ma w. Clin Cancer Res. 2022 Oct 3;28(19):4302-4311. doi: 10.1158/1078-0432.CCR-22-0713. Clin Cancer Res. 2022. PMID: 35849120 Free PMC article.
HER2 Genetic Intratumor Heterogeneity Is Associated With Resistance to Trastuzumab and Trastuzumab Emtansine Therapy in Recurrent High-Grade Endometrial Cancer.
Shen S, Ma W, Brown D, Da Cruz Paula A, Zhou Q, Iaosonos A, Tessier-Cloutier B, Ross DS, Troso-Sandoval T, Reis-Filho JS, Abu-Rustum N, Zhang Y, Ellenson LH, Weigelt B, Makker V, Chui MH. Shen S, et al. Among authors: ma w. Mod Pathol. 2023 Nov;36(11):100299. doi: 10.1016/j.modpat.2023.100299. Epub 2023 Aug 7. Mod Pathol. 2023. PMID: 37558129 Free PMC article.
ERBB2 mutations define a subgroup of endometrial carcinomas associated with high tumor mutational burden and the microsatellite instability-high (MSI-H) molecular subtype.
Brodeur MN, Selenica P, Ma W, Moufarrij S, Dagher C, Basili T, Abu-Rustum NR, Aghajanian C, Zhou Q, Iasonos A, Ellenson LH, Weigelt B, Chui MH. Brodeur MN, et al. Among authors: ma w. Mol Oncol. 2024 Oct;18(10):2356-2368. doi: 10.1002/1878-0261.13698. Epub 2024 Jul 19. Mol Oncol. 2024. PMID: 39031567 Free PMC article.
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.
Modi S, Stopeck AT, Gordon MS, Mendelson D, Solit DB, Bagatell R, Ma W, Wheler J, Rosen N, Norton L, Cropp GF, Johnson RG, Hannah AL, Hudis CA. Modi S, et al. Among authors: ma w. J Clin Oncol. 2007 Dec 1;25(34):5410-7. doi: 10.1200/JCO.2007.11.7960. J Clin Oncol. 2007. PMID: 18048823 Clinical Trial.
Measuring Tumor Epichaperome Expression Using [124I] PU-H71 Positron Emission Tomography as a Biomarker of Response for PU-H71 Plus Nab-Paclitaxel in HER2-Negative Metastatic Breast Cancer.
Jhaveri KL, Dos Anjos CH, Taldone T, Wang R, Comen E, Fornier M, Bromberg JF, Ma W, Patil S, Rodina A, Pillarsetty N, Duggan S, Khoshi S, Kadija N, Chiosis G, Dunphy MP, Modi S. Jhaveri KL, et al. Among authors: ma w. JCO Precis Oncol. 2020 Nov 17;4:PO.20.00273. doi: 10.1200/PO.20.00273. eCollection 2020. JCO Precis Oncol. 2020. PMID: 33283132 Free PMC article.
13,554 results
You have reached the last available page of results. Please see the User Guide for more information.